米氮平与文拉法辛治疗抑郁症临床对照研究

目的:评价米氮平与文拉法辛治疗抑郁症的疗效和不良反应。方法:将符合CCMD-3诊断标准的84例抑郁症住院和门诊患者,随机平分为两组,分别予米氮平和文拉法辛治疗,疗程8周。用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、临床疗效总评量表的病情严重程度(CGI-S1)和副反应量表(TESS)评定疗效和不良反应。结果:米氮平与文拉法辛对抑郁症疗效接近,但前者起效更快,不良反应少于后者。结论:米氮平是一种安全、有效的新一代抗抑郁药,可作为治疗抑郁症的第一线药物使用。

Comparative study of Mirtazapine vs Venlafaxine in the treatment of depression

Objective:To compare efficacy and side effects between Mirtazapine vs Venlafaxine in the treatment of depression.Methods:84 inpatients and outpatients with a diagnosis of depression according to CCMD-3 were involved in this study,they were randomly assigned to the Mirtazapine group(n = 42) and the Venlafaxine group(n = 42) for 8 weeks.Effects and side reactions were evaluated with HAMD,HAMA,CGI-SI and TESS before and after the treatment.Results: Findings indicated that efficacy of Mirtazapine was similar to than of Venlafaxine,however Mirtazapine took effect more quickly and its side effects were less than Venlafaxine.Conclusions: Both Mirtazapine and Venlafaxine have better efficacy and milder side effect in the treatment of depression.Mirtazapine is an effective and safe antidepressant.It is suggested that Mirtazapine could be used as a first-line antidepressant in the treatment of depression.